DGDinesh Giri

Dinesh Giri

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Dinesh Giri has a total of 56 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Delayed dental development and short stature associated with a novel homozygous PAPPA2 variant

    by Erdal Kurnaz, Avinaash Vickram Maharaj, Afiya Andrews, Helen L Storr, Sumana Chatterjee, Dinesh Giri

    Normal human linear growth depends on intact growth hormone (GH) signaling and insulin-like growth factor-I (IGF-I) bioavailability. In the circulation, IGF-I is largely bound to IGF-binding proteins (IGFBPs), predominantly IGFBP-3 and IGFBP-5, which, together with the acid-labile subunit form a ternary complexes that prolong its half-life. Pregnancy-associated plasma protein-A2 (PAPP-A2) cleaves IGFBP-3 and IGFBP-5, releasing bioactive IGF-I. Pathogenic PAPPA2 variants impair this process, reducing IGF-I bioavailability despite elevated total IGF-I concentrations. We report a 12.3-year-old Jordanian girl with short stature and delayed dental development. Biochemical evaluation demonstrated markedly elevated serum IGF-I and high-normal IGFBP-3. Comparative genomic hybridization microarray and targeted sequencing of genes associated with postnatal growth failure, including IGF1R, were unremarkable. A 6-month trial of recombinant human GH produced no measurable growth acceleration; however, interpretation was limited because treatment was commenced when skeletal maturity was advanced. Extended genetic analysis subsequently identified a novel homozygous PAPPA2 frameshift variant, c.1223delT (p.L408Rfs*49). This case expands the molecular spectrum of PAPP-A2 deficiency and highlights the importance of PAPPA2 testing in children with short stature, persistently elevated total IGF-I, and negative IGF1R genetic analysis. Delayed dental development may provide an additional clinical clue and help distinguish PAPP-A2 deficiency from other causes of short stature.

  • Fifteen-minute consultation: the child with early pubic hair

    by Dinesh Giri, Julie Park

    Premature pubarche refers to the early appearance of pubic hair before 8 years of age in girls and 9 years in boys and is most commonly due to premature adrenarche.Premature adrenarche refers to the early appearance of clinical signs of adrenal androgen action, including pubic or axillary hair, body odour, acne, or mild seborrhoea. It is usually a benign variant of normal development. However, similar features may also reflect central precocious puberty, non-classical congenital adrenal hyperplasia, androgen-secreting tumours or exogenous androgen exposure. Distinguishing premature adrenarche from these conditions helps avoid unnecessary investigations while ensuring timely recognition of clinically significant endocrine pathology. This practical 15-minute consultation guide outlines a structured approach to history taking, examination, initial investigations, differential diagnosis and indications for specialist referral.

  • Fifteen-minute consultation: Delayed puberty in girls

    by Emily Morrow, Manju Chandwani, Dinesh Giri

    Delayed puberty in girls most commonly presents as absent breast development by age 13 years and occurs less frequently than delayed puberty in boys. Constitutional delay of growth and puberty (CDGP) is the most common individual diagnosis but pathological causes collectively account for a substantial proportion of cases. For the general paediatrician, a practical assessment framework should include focused history, auxology, Tanner staging, first-line investigations, recognition of red flags and timely referral to paediatric endocrinology. Girls with absent thelarche by age 13 years, absent menarche by age 15 years or no menarche more than 3 years after thelarche require specialist assessment. This article provides a structured clinical guide for general paediatricians assessing girls with delayed puberty.

  • Fifteen-minute consultation: A family-centred approach to recognising and managing differences in sex development

    by Danielle Eddy, Chariklia Pieridou, Eman Kamaleldeen, Julie Alderson, Rachel Caddick, Joanne Williams, Dsdfamilies, Zainaba Mohamed, Dinesh Giri

    Differences of sex development (DSD) comprise a heterogeneous group of congenital conditions affecting urogenital and reproductive development. Variations in sex determination can cause a mismatch between chromosomal, gonadal and phenotypic sex, leading to atypical internal and/or external genitalia. Presentations are varied and most commonly occur in the newborn period and during adolescence. Clinical care is complex and diagnostic pathways may be protracted. Decisions around sex assignment carry ethical considerations and can place a considerable psychological burden on families. This 15-minute guide summarises a practical, stepwise approach for general paediatric and neonatal teams: when to suspect DSD, how to examine and communicate, the first-line investigations to initiate, when/how to escalate to the multidisciplinary DSD service, and how to support families.

  • Open Access

    Mixed Gonadal Dysgenesis: A Comprehensive Review of Clinical Spectrum, Diagnostic Strategies, and Management Approaches

    by Dinesh Giri, Sushil Yewale, Hannah Hickingbotham, Cara Williams, Mohamed Shalaby, Julie Alderson, Julie Park

    Background: Mixed gonadal dysgenesis (MGD) is a rare form of differences in sex development (DSD) typically associated with 45,X/46,XY mosaicism. The phenotypic presentation of MGD varies from atypical genitalia to typical male or female appearances often associated with Turner stigmata. Some of the challenges in the clinical management of patients with MGD include gonadal malignancy risk, decisions on gonadectomy, fertility and sex of rearing. The management is predominantly multidisciplinary with a focus on patient and family centred care. Methods: This article was prepared as a narrative review based on a comprehensive search of the literature. A systematic search of the PubMed, Embase, Scopus, and Google Scholar databases was performed using the key terms “mixed gonadal dysgenesis,” “45,X/46,XY mosaicism,” “differences in sex development,” and “gonadal tumour risk” to identify relevant articles published between 2000 and 2024. References from the identified papers were further screened to capture additional relevant literature. We gathered the findings to provide an updated overview of MGD, focusing on epidemiology, clinical manifestations, diagnostic evaluation, malignancy risk, approaches to management, psychosocial considerations, and evolving strategies in the long‐term care of patients with MGD. Results: MGD accounts for 5%–15% of cases of atypical genitalia and carries a 15%–25% risk of gonadal tumour, with the highest malignancy rates in intra‐abdominal gonads. Approximately 12%–15% of patients with MGD may experience gender incongruence later in life. Management has shifted from early surgical intervention to a multidisciplinary, patient‐centred, and shared decision making approach. Conclusions: The future care of patients with MGD is likely to include biomarker‐driven surveillance, along with advanced fertility preservation techniques. Long‐term outcome data for patients with MGD along with patient‐reported outcomes, are limited in the literature, underscoring the need for further research.


  • 45, X/46, XY mosaicism and gender incongruence: ethical, medical, and psychological considerations

    by Charlotte Horrigan, Julie Alderson, Julie Park, Dinesh Giri

    Objectives: 45, X/46, XY mosaicism is a complex chromosomal difference of sexual development, commonly associated with 45, X/46, XY karyotype. It presents a broad phenotypic spectrum, creating challenges in gender assignment. This report examines the management of a child with 45, X/46, XY mosaicism diagnosed in middle childhood, assigned female at birth but later exhibiting gender incongruence, highlighting dilemmas in pubertal induction after prophylactic gonadectomy. Case presentation: An 8-year-old female presented with differences in sexual development (DSD) following maternal concerns regarding genital appearance. Genetic investigations confirmed a 45, X/46, XY karyotype, leading to bilateral gonadectomy due to malignancy risk. By age 11, the child expressed alignment with being a boy while reluctantly being perceived as a girl. The absence of endogenous sex hormones following gonadectomy will complicate pubertal induction as there is incongruency between the child’s gender preference and the sex of rearing. Conclusions: Limited guidance exists on managing gender incongruence in DSD, particularly regarding pubertal induction. In the UK, while sex assignment at birth is mandated, there is no specific guidance regarding the revision of sex assignment in childhood. A non-coercive environment is essential to support gender exploration whilst balancing medical, psychological, and ethical considerations in decision-making regarding pubertal induction.

  • A recent update on childhood obesity: aetiology, treatment and complications

    by Katherine Hawton, Diksha Shirodkar, Thomas Siese, Julian P. Hamilton-Shield, Dinesh Giri

    Obesity is a complex, chronic condition characterised by excess adiposity. Rates of obesity in childhood and adolescence are increasing worldwide, with a corresponding increase in adulthood. The aetiology of obesity is multifactorial and results from a combination of endocrine, genetic, environmental and societal factors. Population level approaches to reduce the prevalence of childhood obesity worldwide are urgently needed. There are wide-ranging complications from excess weight affecting every system in the body, which lead to significant morbidity and reduced life expectancy. Treatment of obesity and its complications requires a multi-faceted, biopsychosocial approach incorporating dietary, exercise and psychological treatments. Pharmacological treatments for treating childhood obesity have recently become available, and there is further development of new anti-obesity medications in the pipeline. In addition, bariatric surgery is being increasingly recognised as a treatment option for obesity in adolescence providing the potential to reverse complications related to excess weight. In this review, we present an update on the prevalence, aetiology, complications and treatment of childhood obesity.


  • Open Access

    The Enigma That Is ROHHAD Syndrome: Challenges and Future Strategies

    by Katherine Hawton, Dinesh Giri, Elizabeth Crowne, Rosemary Greenwood, Julian Hamilton-Shield

    Rapid-onset obesity with hypoventilation, hypothalamic dysfunction, and autonomic dysregulation (ROHHAD) is a rare syndrome presenting in early childhood associated with a high risk of mortality between 50 and 60%. It is characterised by rapid, early onset of obesity between 1.5–7 years, along with central hypoventilation and hypothalamic dysfunction, such as central hypothyroidism, hyperprolactinemia, disorders of sodium and water balance, growth hormone deficiency, adrenocortical insufficiency, or disorders of puberty and features of autonomic dysregulation. Up to half of cases have neural crest tumours, most commonly ganglioneuromas or ganglioneuroblastomas. The incidence of ROHHAD syndrome in any population is unknown. Currently, there is no specific diagnostic or genetic biomarker for ROHHAD, and diagnosis is based on clinical signs and symptoms, which is often challenging, and consequently may be delayed or unrecognised. Early diagnosis is important, as without intervention, ROHHAD is associated with high morbidity and mortality. Aetiology remains unclear; an autoimmune origin has been postulated, with immunosuppressive agents being used with variable benefit. With no cure, multidisciplinary management is largely supportive. Therefore, there are many unanswered questions in ROHHAD syndrome. In this review article, we outline the challenges posed by ROHHAD syndrome, including aetiology, genetics, diagnosis, screening, management, and prognosis. We present research priorities to tackle these issues to improve outcomes.


  • Open Access

    Insights from the ACTION Teens Study: a survey of adolescents living with obesity, their caregivers and healthcare professionals in the UK

    by Jason C G Halford, Adrian Brown, Kenneth Clare, Louisa J Ells, Anngona Ghosh, Dinesh Giri, Carly Hughes, Senthil Senniappan

    Objectives The Awareness, Care and Treatment In Obesity maNagement (ACTION) Teens study explored attitudes, behaviours, perceptions and barriers regarding effective obesity care among adolescents living with obesity (ALwO), caregivers and healthcare professionals (HCPs). Design Cross-sectional online survey study. Setting Study across 10 countries; here, we report data from UK respondents. Participants Overall, 416 ALwO (aged 12 to Primary and secondary outcome measures Survey questions addressed key aspects of obesity management for ALwO. Results Overall, 46% of ALwO perceived their weight as normal or below normal and 86% believed their health was at least good; 56% and 93% of caregivers responded similarly for their ALwO. Despite this, most ALwO (57%) had attempted to lose weight in the past year and 34% felt highly motivated to lose weight. YouTube and social media were most often used by ALwO for information about weight management (41% and 39%); few ALwO and caregivers sought information from a doctor (13% and 22%). Among ALwO who had discussed weight with an HCP (n=122), 49% trusted their weight-management advice. Only 10% of ALwO and 8% of caregivers were told by a doctor that they/their child had obesity. For HCPs, obesity-related comorbidities were the most common reason for initiating weight conversations with ALwO (73%), while short appointment times were the most common barrier (46%). Overall, 30% of ALwO and 11% of caregivers did not feel comfortable bringing up weight with an HCP. Conclusions Improved education and communication are needed among ALwO, caregivers and HCPs in the UK to help improve awareness of obesity, its aetiology and its impact on health, and to support HCPs to proactively initiate weight-related conversations and build trust with ALwO and caregivers. Trial registration number NCT05013359.


  • Rapid-onset obesity, hypothalamic dysfunction, hypoventilation, and autonomic dysregulation syndrome – neuro-endocrine tumours (ROHHAD-NET): case series and learning points

    by Katherine Hawton, Tom Hilliard, Simon C. Langton-Hewer, Christine Burren, Elizabeth C. Crowne, Julian P. Hamilton-Shield, Dinesh Giri

    Objectives: Rapid-onset obesity with hypoventilation, hypothalamic dysfunction, autonomic dysregulation (ROHHAD) is a rare syndrome associated with high morbidity and mortality. Diagnosis is often challenging. We describe three cases of ROHHAD with heterogeneous presentations but some consistent clinical features, including hyperprolactinaemia at diagnosis. We highlight when the diagnosis of ROHHAD should be considered at an early stage. Case presentation: All three patients presented between 4 and 6 years old with rapid-onset obesity. They all have central hypoventilation requiring nocturnal BiPAP, varying degrees of hypothalamic dysfunction with hyperprolactinaemia being a consistent feature, and autonomic dysfunction. One patient has a neuro-endocrine tumour (NET) and two have glucose dysregulation. Conclusions: High prolactin was a consistent early feature. Central hypoventilation and NET may present later and therefore regular sleep studies and screening for NETs are required. A high suspicion of ROHHAD is warranted in patients with rapid, early-onset obesity and hyperprolactinaemia without structural pituitary abnormality.